Q2 2026 · Form 13F LedgerData source: SEC EDGAR  
H

HOLDER.TOP

Who owns what — the quarterly ledger of U.S. institutional holdings.
EN · 简 · 繁
Funds / Velan Capital Investment Management LP
Form 13F · Q2 2026

Velan Capital Investment Management LP

CIK 1848809Filed 2026-08-1413F-HR View the filing on EDGAR ↗
$164M
Reported book value
53
Positions
12
Quarters on record
Top 50
Positions

Velan Capital Investment Management LP — holdings

Top 50 positions of 53, ranked by reported value. Share change is versus the previous quarter.
#SecuritySharesShare Δ QoQValue% of book
1PRAX Praxis Precision Medicines I88,781−11.9%$30M18.1%
2MPLT Maplight Therapeutics Inc492,893+0.0%$18M10.8%
3STRO Sutro Biopharma Inc512,160+0.0%$17M10.4%
4IMMX Immix Biopharma Inc1.1M+46.6%$11M6.8%
5TARA Protara Therapeutics Inc2.8M+0.4%$11M6.6%
6ABIVAX SA Abivax Sa65,630−14.8%$9M5.3%
7TENX Tenax Therapeutics Inc549,985−5.7%$8M4.9%
8AVR Anteris Technologies Global700,000+0.0%$7M4.2%
9EDSA Edesa Biotech Inc827,500+0.0%$7M4.1%
10EVMN Evommune Inc451,255+1.1%$6M3.7%
11AVTX Avalo Therapeutics Inc324,452+75.3%$6M3.7%
12XNCR Xencor Inc255,000+2.0%$4M2.5%
13RZLT Rezolute Inc750,000+0.0%$4M2.4%
14HRTX Heron Therapeutics Inc8.8M+0.0%$4M2.3%
15VRCA Verrica Pharmaceuticals Inc471,559+0.0%$3M1.8%
16CCCC C4 Therapeutics Inc570,000—$3M1.6%
17EPRX Eupraxia Pharmaceuticals Inc352,000+0.0%$2M1.4%
18ADMA Adma Biologics Inc250,000—$2M1.3%
19RNTX Rein Therapeutics Inc1.7M—$2M1.1%
20LYEL Lyell Immunopharma Inc105,000+2.9%$1M0.9%
21NSRX Nasus Pharma Ltd359,390+0.0%$1M0.8%
22PROF Profound Med Corp170,278−40.4%$1M0.7%
23JSPR Jasper Therapeutics Inc2.7M+0.0%$1M0.7%
24PTGX Protagonist Therapeutics Inc3,700+0.0%$453,5460.3%
25CTMX Cytomx Therapeutics Inc.120,000−77.8%$450,0000.3%
26NMRA Neumora Therapeutics Inc.230,000+187.5%$391,0000.2%
27NRIX Nurix Therapeutics Inc16,000+0.0%$388,1600.2%
28OVID Ovid Therapeutics Inc130,000−18.8%$349,7000.2%
29DTIL Precision Biosciences Inc40,000+0.0%$314,4000.2%
30MLYS Mineralys Therapeutics Inc11,000+0.0%$296,7800.2%
31MGNX Macrogenics Inc60,000+100.0%$277,2000.2%
32CRBP Corbus Pharmaceuticals Hldgs26,000+0.0%$243,8800.1%
33ARTV Artiva Biotherapeutics Inc25,000+0.0%$242,5000.1%
34REPL Replimune Group Inc20,000+0.0%$221,4000.1%
35SNDX Syndax Pharmaceuticals Inc10,000+0.0%$218,6000.1%
36IMNM Immunome Inc10,000+0.0%$211,9000.1%
37TECX Tectonic Therapeutic Inc6,000—$206,2500.1%
38RCKT Rocket Pharmaceuticals Inc60,000−79.6%$205,2000.1%
39KPTIQ Karyopharm Therapeutics Inc20,000+33.3%$195,4000.1%
40ANTX An2 Therapeutics Inc40,000—$193,6000.1%
41VRDN Viridian Therapeutics Inc10,000−89.0%$183,7000.1%
42SCYX Scynexis Inc40,000—$162,8000.1%
43QNRX Quoin Pharmaceuticals Ltd32,372−61.8%$156,6800.1%
44XLO Xilio Therapeutics Inc14,285+0.0%$136,8500.1%
45NSPR Inspiremd Inc148,138−92.9%$103,7110.1%
46KLRS Kalaris Therapeutics Inc25,000+38.9%$101,7500.1%
47LRMR Larimar Therapeutics Inc33,000+0.0%$100,6500.1%
48PROQR THRAPEUTICS N V Proqr Thrapeutics N V45,000+0.0%$83,7000.1%
49CNTX Context Therapeutics Inc59,700−40.3%$33,0680.0%
50GOSS Gossamer Bio Inc70,000+0.0%$11,5220.0%
Source: Form 13F filings via SEC EDGAR. Positions as of Jun 30, 2026. Options (put/call) are excluded from share counts.